Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in first-line metastatic colorectal cancer
NCT06951503Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- May 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in colorectal adenocarcinoma, sponsored by Akeso, Inc.. Started May 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT06951503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951503.